Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Upregulated KPNA2 promotes hepatocellular carcinoma progression and indicates prognostic significance across human cancer types.

Guo X, Wang Z, Zhang J, Xu Q, Hou G, Yang Y, Dong C, Liu G, Liang C, Liu L, Zhou W, Liu H.

Acta Biochim Biophys Sin (Shanghai). 2019 Mar 1;51(3):285-292. doi: 10.1093/abbs/gmz003.

PMID:
30883648
2.

Karyopherin subunit-α 2 expression accelerates cell cycle progression by upregulating CCNB2 and CDK1 in hepatocellular carcinoma.

Gao CL, Wang GW, Yang GQ, Yang H, Zhuang L.

Oncol Lett. 2018 Mar;15(3):2815-2820. doi: 10.3892/ol.2017.7691. Epub 2017 Dec 27.

3.

Silencing of karyopherin α2 inhibits cell growth and survival in human hepatocellular carcinoma.

Yang Y, Guo J, Hao Y, Wang F, Li F, Shuang S, Wang J.

Oncotarget. 2017 May 30;8(22):36289-36304. doi: 10.18632/oncotarget.16749.

4.

Pleomorphic adenoma gene 1 mediates the role of karyopherin alpha 2 and has prognostic significance in hepatocellular carcinoma.

Hu ZY, Yuan SX, Yang Y, Zhou WP, Jiang H.

J Exp Clin Cancer Res. 2014 Jul 25;33:61. doi: 10.1186/s13046-014-0061-1.

5.

Aberrant expression of nuclear KPNA2 is correlated with early recurrence and poor prognosis in patients with small hepatocellular carcinoma after hepatectomy.

Jiang P, Tang Y, He L, Tang H, Liang M, Mai C, Hu L, Hong J.

Med Oncol. 2014 Aug;31(8):131. doi: 10.1007/s12032-014-0131-4. Epub 2014 Jul 17.

PMID:
25031071
6.

KPNA2 promotes cell proliferation and tumorigenicity in epithelial ovarian carcinoma through upregulation of c-Myc and downregulation of FOXO3a.

Huang L, Wang HY, Li JD, Wang JH, Zhou Y, Luo RZ, Yun JP, Zhang Y, Jia WH, Zheng M.

Cell Death Dis. 2013 Aug 1;4:e745. doi: 10.1038/cddis.2013.256.

7.

Nuclear transport receptor karyopherin-α2 promotes malignant breast cancer phenotypes in vitro.

Noetzel E, Rose M, Bornemann J, Gajewski M, Knüchel R, Dahl E.

Oncogene. 2012 Apr 19;31(16):2101-14. doi: 10.1038/onc.2011.403. Epub 2011 Sep 12.

PMID:
21909132
8.

Upregulate KIF4A Enhances Proliferation, Invasion of Hepatocellular Carcinoma and Indicates poor prognosis Across Human Cancer Types.

Hou G, Dong C, Dong Z, Liu G, Xu H, Chen L, Liu L, Wang H, Zhou W.

Sci Rep. 2017 Jun 23;7(1):4148. doi: 10.1038/s41598-017-04176-9.

9.

Quantitative proteomics reveals regulation of karyopherin subunit alpha-2 (KPNA2) and its potential novel cargo proteins in nonsmall cell lung cancer.

Wang CI, Chien KY, Wang CL, Liu HP, Cheng CC, Chang YS, Yu JS, Yu CJ.

Mol Cell Proteomics. 2012 Nov;11(11):1105-22. doi: 10.1074/mcp.M111.016592. Epub 2012 Jul 25.

10.

KPNA2 is overexpressed in human and mouse endometrial cancers and promotes cellular proliferation.

Ikenberg K, Valtcheva N, Brandt S, Zhong Q, Wong CE, Noske A, Rechsteiner M, Rueschoff JH, Caduff R, Dellas A, Obermann E, Fink D, Fuchs T, Krek W, Moch H, Frew IJ, Wild PJ.

J Pathol. 2014 Oct;234(2):239-52. doi: 10.1002/path.4390. Epub 2014 Jul 30.

PMID:
24930886
11.

Karyopherin Alpha 2 Is an Adverse Prognostic Factor in Clear-Cell and Papillary Renal-Cell Carcinoma.

Müller T, Tolkach Y, Stahl D, Steiner S, Hauser S, Ellinger J, Rabien A, Ralla B, Jung K, Stephan C, Kristiansen G.

Clin Genitourin Cancer. 2019 Feb;17(1):e167-e175. doi: 10.1016/j.clgc.2018.10.008. Epub 2018 Oct 23.

PMID:
30448104
12.

Nuclear karyopherin-α2 expression in primary lesions and metastatic lymph nodes was associated with poor prognosis and progression in gastric cancer.

Altan B, Yokobori T, Mochiki E, Ohno T, Ogata K, Ogawa A, Yanai M, Kobayashi T, Luvsandagva B, Asao T, Kuwano H.

Carcinogenesis. 2013 Oct;34(10):2314-21. doi: 10.1093/carcin/bgt214. Epub 2013 Jun 8.

PMID:
23749771
13.

Karyopherin alpha 2 is a novel prognostic marker and a potential therapeutic target for colon cancer.

Zhang Y, Zhang M, Yu F, Lu S, Sun H, Tang H, Peng Z.

J Exp Clin Cancer Res. 2015 Dec 1;34:145. doi: 10.1186/s13046-015-0261-3.

14.

Overexpression of karyopherin-α2 in cholangiocarcinoma correlates with poor prognosis and gemcitabine sensitivity via nuclear translocation of DNA repair proteins.

Tsukagoshi M, Araki K, Yokobori T, Altan B, Suzuki H, Kubo N, Watanabe A, Ishii N, Hosouchi Y, Nishiyama M, Shirabe K, Kuwano H.

Oncotarget. 2017 Jun 27;8(26):42159-42172. doi: 10.18632/oncotarget.15020.

15.

Enhanced karyopherin-α2 expression is associated with carcinogenesis in patients with intraductal papillary mucinous neoplasms.

Kubo N, Araki K, Altan B, Hoshino K, Ishii N, Tsukagoshi M, Igarashi T, Watanabe A, Kato T, Hirai K, Yokobori T, Saito F, Suzuki H, Kuwano H, Shirabe K.

Pancreatology. 2017 Jul - Aug;17(4):611-616. doi: 10.1016/j.pan.2017.04.011. Epub 2017 Apr 23.

PMID:
28476582
16.

Nuclear karyopherin alpha2 expression predicts poor survival in patients with advanced breast cancer irrespective of treatment intensity.

Gluz O, Wild P, Meiler R, Diallo-Danebrock R, Ting E, Mohrmann S, Schuett G, Dahl E, Fuchs T, Herr A, Gaumann A, Frick M, Poremba C, Nitz UA, Hartmann A.

Int J Cancer. 2008 Sep 15;123(6):1433-8. doi: 10.1002/ijc.23628.

17.

Molecular profiling of multiple human cancers defines an inflammatory cancer-associated molecular pattern and uncovers KPNA2 as a uniform poor prognostic cancer marker.

Rachidi SM, Qin T, Sun S, Zheng WJ, Li Z.

PLoS One. 2013;8(3):e57911. doi: 10.1371/journal.pone.0057911. Epub 2013 Mar 25.

18.

KPNA2 is a promising biomarker candidate for esophageal squamous cell carcinoma and correlates with cell proliferation.

Ma S, Zhao X.

Oncol Rep. 2014 Oct;32(4):1631-7. doi: 10.3892/or.2014.3381. Epub 2014 Aug 4.

PMID:
25109899
19.

Knockdown of KPNA2 inhibits autophagy in oral squamous cell carcinoma cell lines by blocking p53 nuclear translocation.

Lin F, Gao L, Su Z, Cao X, Zhan Y, Li Y, Zhang B.

Oncol Rep. 2018 Jul;40(1):179-194. doi: 10.3892/or.2018.6451. Epub 2018 May 17.

20.

Comprehensive analysis of potential prognostic genes for the construction of a competing endogenous RNA regulatory network in hepatocellular carcinoma.

Yue C, Ren Y, Ge H, Liang C, Xu Y, Li G, Wu J.

Onco Targets Ther. 2019 Jan 14;12:561-576. doi: 10.2147/OTT.S188913. eCollection 2019.

Supplemental Content

Support Center